Clinical and public health guidelines · 2025
Protocol for the Development of The Australian Motor Neurone Disease (MND) Guideline.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stern Cindy, Pollock Danielle, Barker Timothy, Holland Grace McKenzie, Hasanoff Sabira, Shrestha Nipun, Semendric Ines, Bulto Lemma Negesa, Sharma Sitasma, Fragkoudi Anna, Facchin-Young Sebastian Cole, Day-Sharman Abigail Molly, Stollery Lara, Beasley-Hall Jay, Schubert Camille, Giles Lynne, Merlin Tracy, Vucic Steve, Whitehouse Jo, Munn Zachary
Аннотация
INTRODUCTION: Motor neurone disease (MND) is a rare but devastating neurodegenerative condition that results in progressive muscle weakness, disability, and eventual respiratory failure. In Australia, the impact of MND is significant, and there is a pressing need for a high-quality, locally relevant guideline to support equitable, person-centred care.
QUESTIONS: This guideline aims to address key clinical and care-related questions that arise across the MND trajectory. It will identify the most pressing topics and uncertainties in MND management through interest holder consultation and structured prioritisation.
METHODS: The guideline will be developed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and will align with standards set by the National Health and Medical Research Council (NHMRC) and the Guidelines International Network (GIN). Governance will include a multi-tiered structure with lived experience representation. Implementation planning and evaluation will be integrated throughout, with a planned transition to a living guideline model supported by an ongoing evidence surveillance strategy.
QUESTIONS: This guideline aims to address key clinical and care-related questions that arise across the MND trajectory. It will identify the most pressing topics and uncertainties in MND management through interest holder consultation and structured prioritisation.
METHODS: The guideline will be developed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and will align with standards set by the National Health and Medical Research Council (NHMRC) and the Guidelines International Network (GIN). Governance will include a multi-tiered structure with lived experience representation. Implementation planning and evaluation will be integrated throughout, with a planned transition to a living guideline model supported by an ongoing evidence surveillance strategy.